Literature DB >> 18212618

A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype.

Iain A M MacPhee1, David W Holt.   

Abstract

Pharmacogenetics has the potential to complement therapeutic drug monitoring in achieving target blood concentrations of the immunosuppressive drugs during the critical early period after transplantation when adequate drug exposure is essential to prevent rejection. The most attractive candidate for a pharmacogenetic strategy is tacrolimus dosing based on the CYP3A5 genotype.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18212618     DOI： 10.1097/TP.0b013e3181609054

Source DB:  PubMed          Journal:  Transplantation        ISSN： 0041-1337            Impact factor:   4.939


  13 in total

1.  The Potential of Pharmacogenomics to Advance Kidney Disease Treatment.

Authors:  Kelly A Birdwell; Cecilia P Chung
Journal:  Clin J Am Soc Nephrol       Date:  2017-06-19       Impact factor: 8.237

Review 2.  Pharmacogenetics and immunosuppressive drugs in solid organ transplantation.

Authors:  Teun van Gelder; Ron H van Schaik; Dennis A Hesselink
Journal:  Nat Rev Nephrol       Date:  2014-09-23       Impact factor: 28.314

3.  Trough level from twice daily to once daily tacrolimus in early conversion kidney transplant recipients: a prospective study.

Authors:  Sayamon Sukkha; Busba Chindavijak; Preecha Montakantikul; Atiporn Ingsathit; Wichit Nosoongnoen; Vasant Sumethkul
Journal:  Int J Clin Pharm       Date:  2017-11-03

4.  The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients.

Authors:  Kelly A Birdwell; Ben Grady; Leena Choi; Hua Xu; Aihua Bian; Josh C Denny; Min Jiang; Gayle Vranic; Melissa Basford; James D Cowan; Danielle M Richardson; Melanie P Robinson; Talat Alp Ikizler; Marylyn D Ritchie; Charles Michael Stein; David W Haas
Journal:  Pharmacogenet Genomics       Date:  2012-01       Impact factor: 2.089

5.  CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients.

Authors:  Nicolas Picard; Koukeb Rouguieg-Malki; Nassim Kamar; Lionel Rostaing; Pierre Marquet
Journal:  Transplantation       Date:  2011-03-27       Impact factor: 4.939

6.  African-American race modifies the influence of tacrolimus concentrations on acute rejection and toxicity in kidney transplant recipients.

Authors:  David J Taber; Mulugeta G Gebregziabher; Titte R Srinivas; Kenneth D Chavin; Prabhakar K Baliga; Leonard E Egede
Journal:  Pharmacotherapy       Date:  2015-05-23       Impact factor: 4.705

7.  Predictive Performance of Published Tacrolimus Population Pharmacokinetic Models in Thai Kidney Transplant Patients.

Authors:  Janthima Methaneethorn; Manupat Lohitnavy; Kamonwan Onlamai; Nattawut Leelakanok
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-11-24       Impact factor: 2.441

8.  Pancreas Transplantation in Black, Asian and Minority Ethnic Patients-Single Centre Experience in the UK.

Authors:  Jeevan Prakash Gopal; Adam McLean; Jeremy Crane; Paul Herbert; Vassilios Papalois; Frank J M F Dor; Anand Rathnasamy Muthusamy
Journal:  Transpl Int       Date:  2022-06-15       Impact factor: 3.842

9.  Factors affecting the long-term response to tacrolimus in renal transplant patients: pharmacokinetic and pharmacogenetic approach.

Authors:  Paraskevi F Katsakiori; Eirini P Papapetrou; George C Sakellaropoulos; Dimitrios S Goumenos; George C Nikiforidis; Christodoulos S Flordellis
Journal:  Int J Med Sci       Date:  2010-05-11       Impact factor: 3.738

Review 10.  The role of genetics in drug dosing.

Authors:  Nicholas Ware
Journal:  Pediatr Nephrol       Date:  2012-02-23       Impact factor: 3.714
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.